Bausch to Dish Out $300M in Pay-to-Delay Settlement

The lawsuit claimed the company paid off generic rivals, allowing the company to increase prices 800%.

A recent FiercePharma article discussed the massive settlement Bausch Health will pay for actions aimed at protecting their diabetes medication Glumetza. The Canadian drugmaker will pay $300 million for a 2019 lawsuit that claims the company paid off generic rivals so that the company could increase prices 800% for their type 2 diabetes drug. The class action lawsuit was driven by direct purchasers of the medication, and was set to go to trial in October.

More in Quick Hits